Crescent Biopharma (CBIO) vs Eupraxia Pharmaceuticals (EPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 29.2% versus a gain of 19.5%. Eupraxia Pharmaceuticals is the larger company by market cap ($514.1 million vs $501.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | EPRX |
|---|---|---|
| Share price | $13.49 | $7.78 |
| Market cap | $501.11M | $514.05M |
| 1-day change | -0.59% | +0.52% |
| YTD return | +13.74% | +3.05% |
| 1-year return | +19.49% | +29.24% |
| 5-year return | -93.19% | — |
| EPS (TTM) | $-7.63 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $9.32 |
| 52-week low | $8.72 | $5.25 |
| Distance from 52-week high | -50.78% | -16.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +133.51% | +110.15% |
| Average volume | 397.58K | 567.95K |
| Shares outstanding | 37.14M | 66.07M |
| Employees | 69 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
CBIO vs EPRX FAQ
Which is bigger, Crescent Biopharma or Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals (EPRX) is larger, with a market capitalization of $514.05M compared with $501.11M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or EPRX?
EPRX returned +29.24% over the past 12 months, compared with +19.49% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Eupraxia Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Crescent Biopharma and Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals.